Calnexin‑Ab‑IBD
Crohn's disease / Ulcerative colitis
PreclinicalActive
Key Facts
Indication
Crohn's disease / Ulcerative colitis
Phase
Preclinical
Status
Active
Company
About Albatroz Therapeutics
Innovative antibodies targeting Calnexin to protect extracellular matrix and treat cancer, arthritis, and IBD.
View full company profile